In a patient with early stage HR+ breast cancer who was perimenopausal at diagnosis but intolerant of AI, would you consider extending tamoxifen beyond 10 years?
In the absence of side effects, would you be inclined to continue beyond 10 years as chemoprevention? Would you factor an intermediate/high oncotype RS into your decision?
Community PollStarted
In a patient with early stage HR+ breast cancer who was perimenopausal at diagnosis but intolerant of AI, would you consider extending tamoxifen beyond 10 years?
30 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · NYU Winthrop Hospital
Answered on
ATLAS and aTTom trial : - 10 years of extended adjuvant Therapy.
In absence of data, I will not extend Adjuvant Therapy.
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Icahn School of Medicine at Mount Sinai
Answered on
It depends upon the characteristics of primary breast cancer. For example, in the case of multi-node positivity, I would extend the duration to ten years total. In stage IA breast cancers, I generally don't extend the duration of anti-estrogen therapy.
In the case of intermediate or high-risk Oncoty...
Join for free or sign in to see the full answer